N/A
N=20
Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Bottom Line
View on ClinicalTrials.gov: NCT07455409 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Number of Participants That Complete ≥ 8 EA Treatments of a 10-treatment EA Program — 18 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Electro-acupuncture (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- The Methodist Hospital Research Institute
- Primary completion
- Aug 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants That Complete ≥ 8 EA Treatments of a 10-treatment EA Program |
18 | — |
| SECONDARY Change in Neuropathic Pain After a 10-treatment EA Program |
5.86; 3.65; 3.71 | — |
| SECONDARY Change in Quality of Life After a 10-treatment EA Program |
56.95; 70.76; 73.85 | — |
Summary
This study will determine the feasibility and efficacy of a 10-treatment electro-acupuncture (EA) program in subjects with chemotherapy-induced peripheral neuropathy (CIPN). The Investigators hypothesize that EA will be a feasible and effective therapy for CIPN.
Eligibility Criteria
Inclusion Criteria
- Male or female aged ≥18 years
- Received curative-intent chemotherapy (i.e., paclitaxel, docetaxel, nab-paclitaxel, carboplatin, oxaliplatin, vinorelbine, ixabepilone, or vincristine) ≥3 months prior to the start of EA treatment
- Persistent Grade ≥2 peripheral neuropathy in the fingers or toes according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
- Eastern Cooperative Oncology Group performance status of ≤2 (see Section 13.3)
- Willing and able to provide written informed consent for the study.
Exclusion Criteria
- Documented medical history of neuropathy resulting from nerve compression (e.g., carpal tunnel syndrome, radiculopathy, or spinal stenosis)
- Severe coagulopathy or bleeding disorder, per the treating physician's discretion
- Presence of cellulitis or other skin infection or condition that would preclude placement of acupuncture needles into the hands or feet
- Diabetes unless Hgb A1c <7.5%
- Unstable cardiac disease
- Pacemaker
- Metal plates
- Known psychiatric disorder that would interfere with cooperation with the requirements of the study
- Pregnant
Data sourced from ClinicalTrials.gov (NCT07455409). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.